Acupuncture for Post COVID-19 Fatigue

Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05749757
Collaborator
(none)
84
2
10

Study Details

Study Description

Brief Summary

The aim of the study is to access the efficacy and safety of acupuncture for post COVID-19 fatigue.

Condition or Disease Intervention/Treatment Phase
  • Device: Acupuncture
  • Device: Sham Acupuncture
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Efficacy and Safety of Acupuncture for Post COVID-19 Fatigue: a Randomized Controlled Trial
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acupuncture

Hwato brand disposable acupuncture needles (size 0.30 × 40 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.

Device: Acupuncture
For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.

Sham Comparator: Sham Acupuncture

Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Guanyuan, Zhongwan, Tianshu, Zusanli, Taixi, Shangyintang, Taiyang, Hegu, Taichong and Shenmen will be selected. Participants will receive a total of 10-session sham acupuncture treatment during four weeks, three times a week in the first two weeks and twice a week in the last two weeks.

Device: Sham Acupuncture
For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.

Outcome Measures

Primary Outcome Measures

  1. The change from baseline in the Chalder Fatigue Scale (CFS) score [Week 4]

    CFS evaluates physical and mental fatigue with two subscales and 11 items. Total fatigue score is obtained by summing 11 items, which were rated on a four-point Likert scale (0=better than usual, 1=no worse than usual, 2=worse than usual, and 3=much worse than usual). Higher scores indicate more severe fatigue.

Secondary Outcome Measures

  1. The change from baseline in the Chalder Fatigue Scale (CFS) score [Weeks 8, 12, and 16]

    CFS evaluates physical and mental fatigue with two subscales and 11 items. Total fatigue score is obtained by summing 11 items, which were rated on a four-point Likert scale (0=better than usual, 1=no worse than usual, 2=worse than usual, and 3=much worse than usual). Higher scores indicate more severe fatigue.

  2. Proportion of participants with a score of less than 15 on CFS [Weeks 4, 8, 12, and 16]

    CFS evaluates physical and mental fatigue with two subscales and 11 items. Total fatigue score is obtained by summing 11 items, which were rated on a four-point Likert scale (0=better than usual, 1=no worse than usual, 2=worse than usual, and 3=much worse than usual). Higher scores indicate more severe fatigue.

  3. The change from baseline in the distance of Six-Minute Walk Test (6MWT). [Weeks 4, 8 and 16]

    The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface.

  4. The proportion of participants rated as "very much improved" or "much improved" based on the Patient Global Impression-Change (PGI-C). [Weeks 4, 8, 12, and 16]

    PGI-C is a 7-point scale, reted by participants themselves, to assess their overall improvement as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse" or "very much worse".

  5. The change from baseline in the score of physical function dimension of Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36). [Weeks 4, 8, 12, and 16]

    Physical functioning of SF-36 is used to assess the health-related quality of life (HRQoL). Physical functioning dimension consists of 10 items with a total score ranging from 0 to 100. Higher scores indicate better HRQoL related to physical functioning.

  6. The change from baseline in the score of Chinese Version of the Work and Social Adjustment Scale (CWSAS). [Weeks 4, 8, 12, and 16]

    The CWSAS assesses the impairment of social function in five items of ability to work, home management, social leisure, private leisure, and close relationship. Each item is rated on a 9-point Likert scale from 0 (no impairment) to 8 (very severe impaired). The total score of the scale ranges from 0 to 40, with higher scores indicating more severe psychopathology.

  7. The change from baseline in the score of Montreal Cognitive Assessment (MoCA). [Weeks 4 and 16]

    The MoCA is used for rapid assessment of mild cognitive impairment. It consists of 12 subtasks exploring the cognitive domains of memory, visuospatial abilities, executive functions, attention, concentration and working memory, language, temporal and spatial orientation. The total score ranges from 0 (worst performance) to 30 (best performance) and the normal score is no less than 26.

  8. The change from baseline in the score of Patient Health Questionnaire-15 (PHQ-15) score. [Weeks 4 and 16]

    PHQ-15 is a self-administered test to assess somatization disorder. It comprises 15 items, and each item scores from 0 ("not bothered at all") to 2 ("bothered a lot").

  9. The change from baseline in the score of Physical Health Questionnaire-9 (PHQ-9) [Weeks 4 and 16]

    The PHQ-9 is a nine-item self-rated questionnaire to measure the severity of depressive symptoms over the last two weeks corresponding to the DSM-IV criteria of major depressive disorder. Each item is scored from 0 (not at all) to 3 (nearly every day). Higher scores indicate greater severity of depressive symptoms.

  10. The change from baseline in the score of General Anxiety Disorder-7 (GAD-7). [Weeks 4 and 16]

    The GAD-7 is a seven-item self-rated questionnaire to assess the severity of generalized anxiety disorder over the last two weeks according to DSM-IV diagnostic criteria. Each item is rated from 0 (not at all) to 3 (nearly every day). Higher scores indicate greater severity of anxiety symptoms.

  11. The change from baseline in the score of Insomnia Severity Index (ISI). [Weeks 4, 8, 12, and 16]

    The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. A 5-point Likert scale (0-4) is used to rate each item and the total score of ISI ranges from 0 to 28. Higher scores indicate more severe insomnia.

Other Outcome Measures

  1. Expectance assessment [Baseline]

    Participants will be asked what do you think the condition of fatigue will be in a month?

  2. Blinding assessment [Within 5 minutes after the either treatment in week 4]

    Participants will be asked do you think you have received traditional acupuncture over the past 4 weeks.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged between 18 and 75.

  • Confirmed COVID-19 infection in the past four weeks to six months, and a negative RT PCR and/or Antigen-Based Rapid Test at present.

  • A main complaint of fatigue emerged newly following COVID-19 infection.

  • A score of ≥15 on Chalder Fatigue Scale (CFS, score range 0-33).

  • Participating the trial volunteerly and providing written informed consent.

Exclusion Criteria:
  • Severe anxiety and depression: a score of ≥25 on 17-item Hamilton Rating Scale for Depression (HAMD-17) and/or a score scores >29 on 14-item Hamilton Rating Scale for Anxiety (HAMA-14).

  • Significant cognitive dysfunction or suicidal tendency.

  • Usage of anti-anxiety and/or anti-depression treatments over the last three months.

  • Previously diagnosed hypothyroidism or chronic fatigue syndrome.

  • A complication of serious and poorly controlled underlying diseases.

  • Having symptoms indicating emergency or severe conditions.

  • Concurrent use of other anti-fatigue agents or treatments at present.

  • Impaired walking ability.

  • Pregnant and/or lactating or planning to get pregnant in the next 4 months.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yuanjie Sun, Principal Investigator, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
ClinicalTrials.gov Identifier:
NCT05749757
Other Study ID Numbers:
  • 2023-013-KY-01
First Posted:
Mar 1, 2023
Last Update Posted:
Mar 2, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2023